Becton Dickinson (BDX) Financial Analysis & Valuation | Quarter Chart
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company&#x... more
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laborator... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $49.86B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | US | CEO | Thomas E. Polen Jr. |
| IPO Date | 1973-02-21 | CAGR | 7.65% |
| Employees | 72,000 | Website | www.bd.com |
| Div. Yield | 0.51% | Payout Ratio | 187% |
| Buy Back Yield | 1.21% | Total Yield | 1.72% |
BDX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $59.10B | P/E | 13.92 | Forward P/E | 13.61 | PEG | -1 |
| P/S | 9.8 | P/B | 8.33 | P/CF | 42.62 | P/FCF | 53.48 |
| Sales | $20.84B | Sales 1Y | -2.56% | Sales 3Y | 9.41% | Sales 5Y | 6.25% |
| EPS | $13 | EPS 1Y | -40.29% | EPS 3Y | -39.75% | EPS 5Y | -47.88% |
| Sales QoQ | 5.71% | EPS QoQ | -223.42% | Sales QoQ Avg | -2.11% | EPS QoQ Avg | -110.59% |
| Gross Margin | 46.12% | Operating Margin | 9.83% | Profit Margin | 4.52% | ROCE | 4.96% |
| ROA | 2% | ROE | 4% | Altman Z Score | 2.15 | Piotroski Score | 7 |
| Current Ratio | 0.87 | Quick Ratio | 0.51 | Cash Ratio | 0.08 | Op. CF Ratio | 0.22 |
| Debt/Equity | 0.69 | Debt/Assets | 0.33 | Lt Debt/Equity | 0.55 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 3.77 | Inventory Turnover | 3.39 | Asset Turnover | 0.41 | Receivables Turnover | 8.82 |
| Enterprise Value | $59.10B | P/E Ratio | 13.92 |
| Forward P/E | 13.61 | PEG Ratio | -1 |
| P/S Ratio | 9.8 | P/B Ratio | 8.33 |
| P/CF Ratio | 42.62 | P/FCF Ratio | 53.48 |
| EPS | $13 | EPS Growth 1Y | -40.29% |
| EPS Growth 3Y | -39.75% | EPS Growth 5Y | -47.88% |
| Revenue Growth 1Y | -2.56% | Gross Margin | 46.12% |
| Operating Margin | 9.83% | Profit Margin | 4.52% |
| ROE | 4% | ROA | 2% |
| ROCE | 4.96% | Current Ratio | 0.87 |
| Quick Ratio | 0.51 | Cash Ratio | 0.08 |
| Debt/Equity | 0.69 | Interest Coverage | 3.77 |
| Altman Z Score | 2.15 | Piotroski Score | 7 |
Becton Dickinson (BDX) valuation & financials
Becton Dickinson (BDX) has a market capitalization of $49.86B and trades at a price-to-earnings ratio of 13.9. It operates in the Healthcare sector (Medical - Instruments & Supplies).
Becton Dickinson's revenue grew -2.6% over the last year.
Becton Dickinson's next earnings report is scheduled for November 5, 2026 before market open (provider scheduled date); analysts estimate EPS of $4.06. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)